Sermorelin vs VIP (Vasoactive Intestinal Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Dose Range | 100 mcg–300 mcg | 100 mcg–200 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 8–12 weeks | 2–8 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. |
| Typical Dosage | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. |
| Administration | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. |
| Side Effects | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. |
| Best For |
What They Have in Common
Sermorelin, VIP (Vasoactive Intestinal Peptide) are both commonly used for:
Key Differences
Unique to Sermorelin:
Unique to VIP (Vasoactive Intestinal Peptide):
Which Has Stronger Evidence?
- Sleep Quality: Sermorelin has stronger research support.
| Goal | Sermorelin | VIP (Vasoactive Intestinal Peptide) |
|---|---|---|
| Sleep Quality | medium | low |
Key Studies
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
VIP (Vasoactive Intestinal Peptide)
- Distribution of vasoactive intestinal peptide (VIP) immunoreactivity in the rat pallial and subpallial amygdala and colocalization with γ-aminobutyric acid (GABA).
Anatomical record (Hoboken, N.J. : 2007), 2024
- Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF.
Frontiers in endocrinology, 2024
- Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis.
Frontiers in pharmacology, 2021
Ready to Learn More?
Looking for trusted sources?